In the realm of rare diseases, Fabry Disease stands out as a significant challenge for patients and healthcare providers alike. This genetic disorder, characterized by the deficiency of an enzyme called alpha-galactosidase A (α-GAL A), leads to the accumulation of glycolipids in various organs, causing progressive and potentially life-threatening complications. Fabry Disease Market Share...